Symbols / MBIO
MBIO Chart
About
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.37M |
| Enterprise Value | -11.61M | Income | -2.33M | Sales | — |
| Book/sh | 1.34 | Cash/sh | 2.60 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | -2.89 | PEG | — |
| P/S | — | P/B | 0.75 | P/C | — |
| EV/EBITDA | 7.03 | EV/Sales | — | Quick Ratio | 2.03 |
| Current Ratio | 2.05 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -6.71 | EPS next Y | -0.35 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-03-28 08:00 | ROA | -8.17% |
| ROE | -4.19% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.45M |
| Shs Float | 5.07M | Short Float | 0.68% | Short Ratio | 0.70 |
| Short Interest | — | 52W High | 7.00 | 52W Low | 0.53 |
| Beta | 2.16 | Avg Volume | 201.79K | Volume | 30.11K |
| Target Price | — | Recom | None | Prev Close | $0.99 |
| Price | $1.01 | Change | 2.03% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.01
Latest analyst target
3. DCF / Fair value
$-10.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-05-13 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-08-24 | reit | Cantor Fitzgerald | Overweight → Overweight | $18 |
| 2023-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-08-15 | main | BTIG | Buy → Buy | $16 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-06-16 | main | BTIG | — → Buy | $20 |
| 2023-06-16 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
- Breakthrough Brain Cancer Treatment: FDA Backs Mustang Bio Therapy After 66-Month Complete Response in Trials - Stock Titan Mon, 07 Jul 2025 07
- MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - Nasdaq ue, 08 Jul 2025 07
- MindBio Announces Stock Consolidation - TheNewswire Mon, 03 Nov 2025 08
- symbol__ Stock Quote Price and Forecast - CNN hu, 18 Jan 2024 20
- Should I average down on MBIO stock - 2025 Key Highlights & High Win Rate Trade Alerts - mfd.ru Mon, 16 Feb 2026 10
- Mustang Bio Stock Surges: Time to Reconsider? - StocksToTrade Mon, 07 Jul 2025 07
- Insider Traders Lose AU$107k As MindBio Therapeutics Drops - simplywall.st Wed, 21 May 2025 07
- Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga Wed, 09 Jul 2025 07
- An antisense oligomer conjugate with unpredicted bactericidal activity against Fusobacterium nucleatum | mBio - ASM Journals ue, 29 Apr 2025 07
- Why Is Mustang Bio (MBIO) Stock Up 347% Today? - InvestorPlace Mon, 17 Jun 2024 07
- Mustang Bio (MBIO) Stock Forecast and Price Target 2026 - MarketBeat Sat, 11 May 2024 13
- Mustang Bio’s Meteoric Surge: What’s Driving Up MBIO? - StocksToTrade Wed, 09 Jul 2025 07
- Mustang Bio’s CAR-T MB-106 Achieves Responses in 9 of 10 Patients With Waldenstrom Macroglobulinemia - CGTLive® ue, 18 Jun 2024 07
- Immunological correlates of protection mediated by a whole organism, Cryptococcus neoformans , vaccine deficient in chitosan - ASM Journals Fri, 19 Jul 2024 03
- MBIO - Mustang Bio Latest Stock News & Market Updates - Stock Titan Sun, 06 Sep 2020 05
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 278385 | — | — | Stock Award(Grant) at price 0.00 per share. | FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-02 00:00:00 | D |
| 1 | 247 | 238.0 | — | Sale at price 0.96 per share. | HERSKOWITZ NEIL | Director | — | 2025-12-30 00:00:00 | D |
| 2 | 4 | 4.0 | — | Sale at price 0.95 per share. | CHILL ADAM J | Director | — | 2025-12-30 00:00:00 | D |
| 3 | 247 | 238.0 | — | Purchase at price 0.96 per share. | JIN DAVID | Director | — | 2025-12-30 00:00:00 | D |
| 4 | 59334 | — | — | Stock Award(Grant) at price 0.00 per share. | FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-29 00:00:00 | D |
| 5 | 67806 | — | — | Stock Award(Grant) at price 0.00 per share. | FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-31 00:00:00 | D |
| 6 | 575191 | nan | — | — | FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-06-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.23M | -46.73M | -71.14M | -64.05M |
| TotalUnusualItems | -3.69M | -1.33M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -3.69M | -1.33M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.75M | -51.60M | -77.53M | -66.37M |
| ReconciledDepreciation | 823.00K | 2.23M | 3.03M | 2.31M |
| EBITDA | -14.92M | -48.06M | -71.14M | -64.05M |
| EBIT | -15.75M | -50.29M | -74.17M | -66.36M |
| NetInterestIncome | 179.00K | -463.00K | -2.67M | 353.00K |
| InterestExpense | 5.00K | 1.31M | 3.36M | 15.00K |
| InterestIncome | 184.00K | 850.00K | 689.00K | 368.00K |
| NormalizedIncome | -12.06M | -50.27M | -77.53M | -66.37M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.75M | -51.60M | -77.53M | -66.37M |
| TotalExpenses | 12.55M | 50.73M | 76.16M | 66.72M |
| TotalOperatingIncomeAsReported | -16.25M | -49.26M | -76.16M | -66.72M |
| DilutedAverageShares | 609.70K | 172.03K | 137.91K | 117.18K |
| BasicAverageShares | 609.70K | 172.03K | 137.91K | 117.18K |
| DilutedEPS | -38.57 | -299.95 | -562.50 | -570.00 |
| BasicEPS | -38.57 | -299.95 | -562.50 | -570.00 |
| DilutedNIAvailtoComStockholders | -15.75M | -51.60M | -77.53M | -66.37M |
| NetIncomeCommonStockholders | -15.75M | -51.60M | -77.53M | -66.37M |
| NetIncome | -15.75M | -51.60M | -77.53M | -66.37M |
| NetIncomeIncludingNoncontrollingInterests | -15.75M | -51.60M | -77.53M | -66.37M |
| NetIncomeContinuousOperations | -15.75M | -51.60M | -77.53M | -66.37M |
| PretaxIncome | -15.75M | -51.60M | -77.53M | -66.37M |
| OtherIncomeExpense | -3.38M | -413.00K | 1.30M | |
| OtherNonOperatingIncomeExpenses | 314.00K | 917.00K | 1.30M | |
| SpecialIncomeCharges | -3.69M | -1.33M | 0.00 | |
| GainOnSaleOfPPE | 0.00 | 1.47M | 0.00 | |
| OtherSpecialCharges | 2.80M | |||
| WriteOff | 3.69M | 0.00 | ||
| ImpairmentOfCapitalAssets | 3.69M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 179.00K | -463.00K | -2.67M | 353.00K |
| InterestExpenseNonOperating | 5.00K | 1.31M | 3.36M | 15.00K |
| InterestIncomeNonOperating | 184.00K | 850.00K | 689.00K | 368.00K |
| OperatingIncome | -12.55M | -50.73M | -76.16M | -66.72M |
| OperatingExpense | 12.55M | 50.73M | 76.16M | 66.72M |
| OtherOperatingExpenses | -1.30M | |||
| ResearchAndDevelopment | 8.42M | 41.04M | 63.95M | 55.71M |
| SellingGeneralAndAdministration | 4.13M | 9.69M | 12.21M | 11.02M |
| GeneralAndAdministrativeExpense | 4.13M | 9.69M | 12.21M | 11.02M |
| OtherGandA | 4.13M | 9.69M | 12.21M | 11.02M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.83M | 1.01M | 198.36K | 181.14K |
| ShareIssued | 1.83M | 1.01M | 198.36K | 181.14K |
| TotalDebt | 878.00K | 2.50M | 31.38M | 2.03M |
| TangibleBookValue | -3.87M | 123.00K | 46.27M | 112.40M |
| InvestedCapital | -3.87M | 123.00K | 73.71M | 112.40M |
| WorkingCapital | -4.00M | -4.03M | 63.74M | 100.89M |
| NetTangibleAssets | -3.87M | 123.00K | 46.27M | 112.40M |
| CapitalLeaseObligations | 878.00K | 2.50M | 3.95M | 2.03M |
| CommonStockEquity | -3.87M | 123.00K | 46.27M | 112.40M |
| TotalCapitalization | -3.87M | 123.00K | 73.71M | 112.40M |
| TotalEquityGrossMinorityInterest | -3.87M | 123.00K | 46.27M | 112.40M |
| StockholdersEquity | -3.87M | 123.00K | 46.27M | 112.40M |
| OtherEquityInterest | 611.00K | 591.00K | 1.11M | 4.33M |
| RetainedEarnings | -396.72M | -380.97M | -329.37M | -251.84M |
| AdditionalPaidInCapital | 392.23M | 380.50M | 374.52M | 359.91M |
| CapitalStock | 5.00K | 1.00K | 11.00K | 9.00K |
| CommonStock | 5.00K | 1.00K | 11.00K | 9.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 13.18M | 17.62M | 46.15M | 12.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 572.00K | 2.25M | 31.04M | 1.96M |
| NonCurrentDeferredLiabilities | 150.00K | 270.00K | 270.00K | 270.00K |
| NonCurrentDeferredRevenue | 150.00K | 270.00K | 270.00K | 270.00K |
| LongTermDebtAndCapitalLeaseObligation | 422.00K | 1.98M | 30.77M | 1.69M |
| LongTermCapitalLeaseObligation | 422.00K | 1.98M | 3.33M | 1.69M |
| LongTermDebt | 27.44M | |||
| CurrentLiabilities | 12.61M | 15.37M | 15.11M | 10.81M |
| CurrentDebtAndCapitalLeaseObligation | 456.00K | 520.00K | 612.00K | 348.00K |
| CurrentCapitalLeaseObligation | 456.00K | 520.00K | 612.00K | 348.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 93.00K | 2.84M | 3.47M | 2.60M |
| PayablesAndAccruedExpenses | 12.06M | 12.01M | 11.03M | 7.87M |
| CurrentAccruedExpenses | 1.93M | 4.86M | 3.43M | 3.64M |
| Payables | 10.13M | 7.16M | 7.60M | 4.24M |
| DuetoRelatedPartiesCurrent | 2.67M | 834.00K | 766.00K | 723.00K |
| AccountsPayable | 7.46M | 6.32M | 6.83M | 3.51M |
| TotalAssets | 9.31M | 17.74M | 92.42M | 125.17M |
| TotalNonCurrentAssets | 702.00K | 6.40M | 13.57M | 13.46M |
| OtherNonCurrentAssets | 250.00K | 1.58M | 1.26M | 1.36M |
| NetPPE | 452.00K | 4.81M | 12.31M | 12.10M |
| AccumulatedDepreciation | -7.32M | -4.48M | -8.40M | -5.73M |
| GrossPPE | 7.78M | 9.29M | 20.71M | 17.84M |
| Leases | 7.69M | 7.69M | 7.69M | 7.69M |
| ConstructionInProgress | 0.00 | 29.00K | 951.00K | 2.03M |
| OtherProperties | 81.00K | 1.57M | 2.92M | 1.05M |
| MachineryFurnitureEquipment | 0.00 | 9.15M | 7.07M | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.61M | 11.35M | 78.85M | 111.71M |
| OtherCurrentAssets | 200.00K | 1.23M | 2.90M | 2.04M |
| AssetsHeldForSaleCurrent | 1.17M | 0.00 | ||
| PrepaidAssets | 2.04M | |||
| Receivables | 402.00K | 3.88M | 299.00K | 50.00K |
| OtherReceivables | 402.00K | 3.88M | 263.00K | |
| DuefromRelatedPartiesCurrent | 0.00 | 36.00K | 50.00K | |
| CashCashEquivalentsAndShortTermInvestments | 6.84M | 6.23M | 75.66M | 109.62M |
| CashAndCashEquivalents | 6.84M | 6.23M | 75.66M | 109.62M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.41M | -49.59M | -68.14M | -59.03M |
| RepaymentOfDebt | 0.00 | -30.38M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 30.00M | 0.00 | |
| IssuanceOfCapitalStock | 9.15M | 4.56M | 6.62M | 71.92M |
| CapitalExpenditure | -114.00K | -3.08M | -5.37M | |
| InterestPaidSupplementalData | 0.00 | 1.34M | 2.71M | 0.00 |
| EndCashPosition | 6.84M | 6.98M | 76.66M | 110.62M |
| BeginningCashPosition | 6.98M | 76.66M | 110.62M | 98.80M |
| ChangesInCash | -145.00K | -69.67M | -33.96M | 11.81M |
| FinancingCashFlow | 11.27M | -26.08M | 34.06M | 70.85M |
| CashFlowFromContinuingFinancingActivities | 11.27M | -26.08M | 34.06M | 70.85M |
| NetOtherFinancingCharges | -1.46M | -445.00K | -2.77M | -1.38M |
| ProceedsFromStockOptionExercised | 3.57M | 178.00K | 206.00K | 309.00K |
| NetCommonStockIssuance | 9.15M | 4.56M | 6.62M | 71.92M |
| CommonStockIssuance | 9.15M | 4.56M | 6.62M | 71.92M |
| NetIssuancePaymentsOfDebt | 0.00 | -30.38M | 30.00M | 0.00 |
| NetShortTermDebtIssuance | 0.00 | -30.38M | ||
| ShortTermDebtPayments | 0.00 | -30.38M | ||
| NetLongTermDebtIssuance | -30.38M | 30.00M | 0.00 | |
| LongTermDebtPayments | -30.38M | 0.00 | 0.00 | |
| LongTermDebtIssuance | 0.00 | 30.00M | 0.00 | |
| InvestingCashFlow | 0.00 | 5.89M | -2.95M | -5.37M |
| CashFlowFromContinuingInvestingActivities | 0.00 | 5.89M | -2.95M | -5.37M |
| NetIntangiblesPurchaseAndSale | 0.00 | -50.00K | -365.00K | -1.38M |
| PurchaseOfIntangibles | 0.00 | -50.00K | -365.00K | -1.38M |
| NetPPEPurchaseAndSale | 0.00 | 5.94M | -2.59M | -3.99M |
| SaleOfPPE | 0.00 | 6.00M | 127.00K | 0.00 |
| PurchaseOfPPE | 0.00 | -64.00K | -2.71M | -3.99M |
| OperatingCashFlow | -11.41M | -49.48M | -65.07M | -53.67M |
| CashFlowFromContinuingOperatingActivities | -11.41M | -49.48M | -65.07M | -53.67M |
| ChangeInWorkingCapital | -628.00K | -2.98M | 4.03M | -637.00K |
| ChangeInOtherWorkingCapital | -120.00K | 270.00K | ||
| ChangeInOtherCurrentLiabilities | -447.00K | -680.00K | -263.00K | -296.00K |
| ChangeInPayablesAndAccruedExpense | -1.14M | 192.00K | 5.30M | -175.00K |
| ChangeInPayable | 192.00K | 5.30M | -175.00K | |
| ChangeInAccountPayable | 192.00K | 5.30M | -175.00K | |
| ChangeInPrepaidAssets | 586.00K | 1.09M | -1.01M | -401.00K |
| ChangeInReceivables | 494.00K | -3.58M | -1.00K | -35.00K |
| OtherNonCashItems | 876.00K | 978.00K | 2.86M | 7.73M |
| StockBasedCompensation | -450.00K | 568.00K | 2.28M | 3.31M |
| AssetImpairmentCharge | 3.69M | 0.00 | ||
| DepreciationAmortizationDepletion | 823.00K | 2.23M | 3.03M | 2.31M |
| DepreciationAndAmortization | 823.00K | 2.23M | 3.03M | 2.31M |
| Depreciation | 823.00K | 2.23M | 3.03M | 2.31M |
| OperatingGainsLosses | 29.00K | 1.33M | 255.00K | |
| GainLossOnSaleOfPPE | 29.00K | -1.47M | 255.00K | 0.00 |
| NetIncomeFromContinuingOperations | -15.75M | -51.60M | -77.53M | -66.37M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MBIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|